Previous 10 | Next 10 |
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report PR Newswire Institute for Clinical and Economic Review (ICER) Base-Ca...
Commercial-stage biotech BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN ) announced Monday that investigations are underway after a patient in its Phase 3 trial for its Hemophilia A candidate BMN 270 was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). Citing initial...
BioMarin (BMRN) has received European approval for its gene therapy for Hemophilia A, explains John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter. For further details see: BioMarin- Progress in Treating Hemophilia
Summary Shares have fallen by 30% so far in 2022. Durability and safety for the Fabry disease gene therapy program continues to look best-in-class and enrollment should accelerate due to investigator enthusiasm. Excitement is palpable for CAR-Treg programs as renal transplant ...
Announcing the EU approval of Roctavian for hemophilia A, BioMarin Pharmaceutical ( NASDAQ: BMRN ) disclosed its plans to resubmit the U.S. marketing application for the gene therapy to the FDA by the end of next month. In 2020, the agency rejected the one-time infusion, a...
First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC) PR Newswire Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity Signif...
BioMarin Pharmaceuticals ( NASDAQ: BMRN ) may be a potential activist investor target after 13-F filings from some prime brokers. Barclays added over 2 million BioMarin ( BMRN ) shares in Q2 and had a 1.2% as of the end of June, according to a 13-filing. The Barcla...
BioMarin Pharmaceutical Inc. (BMRN) Q2 2022 Earnings Conference Call August 3, 2022 16:30 ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Ch...
BioMarin Pharmaceutical has boosted its 2022 GAAP net income and net revenue outlook following Q2 2022 growth in product sales. The biotech is now projecting GAAP net income of $105M-$145M, up from $95M-$135M. Total revenues are now estimated at $2.06B-$2.16B, up from $2.05B-$2.15...
BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q2 GAAP EPS of $0.15 beats by $0.06 . Revenue of $533.8M (+6.4% Y/Y) beats by $11.87M . Shares -2% . Total revenue of $2.06B-$2.16B from prior outlook of $2.05B-$2.15B vs. $2.11B consensus. Re-...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...